RO7126209

PreclinicalSmall molecule

RO7126209 is one of 5 small molecule programs targeting Mild to Moderate Alzheimer's Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mild to Moderate Alzheimer's DiseaseActive, not recruiting

Mild to Moderate Alzheimer's DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Mild to Moderate Alzheimer's Disease

#DrugCompanyPhaseTrials

Choline Alfoscerate

Chong Kun Dang Pharmaceutical

Phase 3

1 2

Sodium Pentaborate

TTabriz University of Medical Sciences

Phase 2

1 3

Neuroepo

IInternational Center for Neurological Restoration, Cuba

Phase 2

1 4

RB-ADSC

RRegeneration Biomedical, Inc.

Phase 1

1 5

RO7126209

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalActive, not recruiting

Alzheimer's Disease

NCT04639050

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Completed· Roche logo

Roche·Phase 1·NCT04023994·36 enrolled

Alzheimer's Disease1 trial

A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease

Active, not recruiting· Roche logo

Roche·Preclinical·NCT04639050·241 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for RO7126209. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO7126209 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO7126209. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Roche

RO7126209

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Single Ascending Dose1 trial

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News